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Sinmary Relatively little is known about the epidemiology of carcinoid tumours in contrast to the extensive
information available on their biochemical effects and natural history. Accordingly, we have used cancer
regtstrations in England from 1979 to 1987, and in Scotland from 1980 to 1989, to estimate the incidence of
carcinoid tumours in Britain Age-standardised incidence rates for England, based on 3,382 registrations, were
0.71 (0.68-0.75) for men and 0.87 (0.83-0.91) for women, per 100,000 per year. The equivalent rates for
Scotland, based on 639 registrations, were 1.17 (0.91-1.44) for men and 1.36 (1.09-1.63) for women. There
was a consistent female excess ofcarcinoid tumours in the reproductive years, which was reversed after the age
of 50. The female excess was most striking for gastrointestinal carcinoid tumours in women aged 15-19 years
(F:M ratio = 2.14). The sex differences are probably due in part to incidental diagnosis of carcinoid tumours
during abdominal procedures, which are more common in women than men at ages 15-49 years. However,
there is some evidence to suggest a true sex difference in incidence, particularly the fact that the sex ratio for
thoracic tumours varies with age in a similar way to that for gastrointestinal tumours. Hormonal factors may,
therefore, be important in the aetiology of carcinoid tumours.
Carcinoid tumours were so named by Oberndorfer in 1907
because they resembled carcinomas but were thought to be of
a more benign nature (Grahame-Smith, 1972). Since then the
malignant potential of these tumours has been recognised.
MacDonald (1956) has suggested that all extra-appendiceal
carcinoids should be considered potentially malignant. Car-
cinoid tumours are the most common tumour of the appen-
dix, the most common gastrointestinal neuroendocrine
tumour and the most common form of bronchial adenoma.
They may present with non-specific abdominal symptoms,
with local symptoms such as haemorrhage or obstruction of
the bowel or a bronchus, with evidence of metastasis or with
the malignant carcinoid syndrome. This syndrome, first des-
cribed in 1934, is characterised by facial flushing, bron-
choconstriction, episodic diarrhoea and right-sided valvular
heart disease (Cassidy, 1934; Grahame-Smith, 1972). It is
found in less than 10% of patients with carcinoid tumours in
most case series, and generally only after the tumour has
metastasised. Many carcinoid tumours are asymptomatic and
are found incidentally, for example at appendicectomy or at
post-mortem (Berge & Linell, 1976).
Although a number of aspects of carcinoid tumours have
been studied in detail, relatively little is known about their
epidemiology and no aetiological factors have been estab-
lished (Basser & Green, 1991). It is difficult to derive
incidence rates from the many published case series because
of uncertain denominators and potential referral biases. The
few population-based studies from the UK (Watson et al.,
1989; Woods et al., 1990) have not been large enough to
analyse risks by age and sex, and there are few population-
based studies from elsewhere (Godwin, 1975; Weiss & Yang,
1987).
Methods
In both England and Scotland, mortality statistics for car-
cinoid tumours are not available from routine sources.
Cancer deaths in Britain are coded according to the site of
the primary tumour not its histological characteristics.
Cancer registrations, on the other hand, include information
on the site of the primary tumour (if known) and its mor-
phology. Cancer registration in Britain began in 1929 (Stiller,
1993). Coverage has been national in England since 1962 and
in Scotland since 1959. Regional registries send data to the
national cancer registries at the Office of Population Cen-
suses and Surveys (OPCS) in England and the Information
and Statistics Division of the Common Services Agency in
Scotland.
England
Cancer registration data were obtained from the OPCS on all
carcinoid tumours first registered in 1979-87 in English
residents. Although the OPCS also holds Welsh data, these
could not be used in this study because they rarely include
tumour morphology codes. Registrations of carcinoid
tumours were identified using morphology codes 8240-8244
from the International Classification of Diseases for
Oncology (ICD-O) (WHO, 1976). The tumours had been
given either malignant site codes (ICD-9 140-208) (WHO,
1977) or site codes which indicated that their future
behaviour was uncertain (ICD-9 235-238). Before 1979,
when ICD-8 (WHO, 1%9) was used, tumours of uncertain
behaviour were not coded separately from benign tumours
and were not recorded by cancer- registries. The majority of
carcinoid tumours are of uncertain malignancy. This study,
therefore, was restricted to the period after 1979 when only
tumours specifically reported as benign by the pathologist
would not have been registered.
Registrations were subdivided according to tumour site
using the ICD-9 classification. Where necessary individual
site codes were aggregated as follows: 'gastrointestinal
tumours' ICD-9 150.0-154.8 and 235.2; 'thoracic tumours'
ICD-9 162.0-165.9, 235.7 and 235.8. The uncertain codes are
less specific with respect to site than the malignant codes (see
Table I). The natural history of carcinoid tumours is such
that the distinction between a malignant tumour and one of
potential malignancy is not easily made. On examination of
the data, there seemed to be inconsistency among registries in
the proportion of cases assigned a malignant, as opposed to
an uncertain, site code. Because of this evidence of crossover
between the categories we did not analyse malignant tumours
separately from those of uncertain behaviour.
As the coding of carcinoid tumours is relatively complex,
we conducted a simple telephone survey of registry coding
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practice for these tumours in England. This showed that
similar coding rules existed in all registries. Only two regis-
tries did not routinely receive pathology reports on all
cancers as well as information from death certificates and
other sources. The Thames Registry receives information in
electronic format from staff working in the field. In Trent,
registrations are generated by hospital records staff from
information held on hospital information systems and the
registry then obtains pathological information from the
clinical notes or from the clinician directly. For the surveil-
lance of carcinoid tumours hospital activity information
systems are likely to be less sensitive than a system which
includes direct reporting by pathology laboratories.
In order to estimate the completeness of registration of
carcinoid tumours using information already to hand, Eng-
lish registries were searched for records of 17 patients known
by one of us (D.G.S.) to have had a carcinoid tumour
diagnosed histologically. A more formal test of completeness
was beyond the scope of this study.
Scotland
Data were obtained from the Scottish Common Services
Agency on all carcinoid tumours first registered in the years
1980-89 in residents of Scotland. Tumours with malignant
or uncertain site codes, ICD-9 140-208 and 235-238, were
included. Because the number of tumours was smaller than
for England, they were not analysed by site.
Statistical methods
Overall rates were directly age standardised using the popula-
tion of England and Wales in 1981 as a standard for both
English and Scottish data. Confidence intervals were cal-
culated using the Poisson approximation to the normal dis-
tribution.
Results
England
In the period 1979-87, there were 3,382 carcinoid tumours
registered in England. Age-standardised registration rates per
100,000 per year (95% Cl) were 0.71 (0.68-0.75) in men and
0.87 (0.83-0.91) in women. The distribution of these
tumours by site and behaviour, which was similar in males
and females, is given in Table I. Figure 1 shows age- and
sex-specific mean annual registration rates for all sites. The
incidence rates increased with age in each sex, but declined
sharply after 80 years. Incidence rates were consistently
greater for females than males throughout the reproductive
years. There was a sharp peak in women aged 15-19 years
Table I Registered carcinoid tumours in England (1979-87) by site
and behaviour
ICD-9
code Site n %
Malignant tumours
152 Small intestine 378 11.2
153 Colon (including appendix) 343 10.1
162 Trachea, bronchus, lung 203 6.0
197, 198, 199 Disseminated tumour 129 3.8
154 Rectum 44 1.3
151 Stomach 39 1.2
Other sites 121 3.6
Twnours ofuncertai behaviour
2352 Stomach, intestines, rectum 1,544 45.7
2357, 2358 Thorax 410 12.1
Other sites 171 5.0
Total 3,382 100
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which was not seen in males. After the age of 50 years the
sex difference was reversed. Analysis of information from
each registry separately (data not reported) showed that these
sex differences were not due to anomalous results from any
one registry. Figures 2 and 3 show similar data separately for
gastrointestinal and thoracic tumours respectively. Gastro-
intestinal tumours were relatively more common in younger
age groups compared with thoracic tumours. The peak of
incidence in women aged 15-19 years was only seen for
gastrointestinal tumours. The female excess in the
reproductive years was apparent in both gastrointestinal and
thoracic tumours.
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Figue 2 Age- and sex-specific incidence rates of carcinoid
tumours in England, 1979-87, gastrointestinal sites only. *,
Male; 0, female.
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The test of completeness showed that 15 out of 17 cases
independently known to us (see Methods) had been corrctly
registered in four different registries. One of the remaining
two cases was incorrectly registered as a prostatic cancer and
the other was not registered.
Scotland
In Scodand, 639 carcnoid tumours were registered m the
period 1980-89. Age-standardised registration rates per
100,000 per year were 1.17 (0.91-1.44) in men and 1.36
(1.09-1.63) in women. Figure 4 shows age- and sex-specific
registration rates for Scotland. Registered inidene rates
were generally higher in Scotland than in England, parti-
cularly in older age groups. There was no clear peak in
women aged 15-19 years, but there was a female excess in
the reproductive period.
This investigation is one of a small number of population-
based studies of carcinoid tumours. Based on four thousand
registrations, it is much larger than previous studies from the
UK, none of which have presented data on the age and sex
distribution of the tumours. The valdity of our results, how-
ever, depends on the completeness and accuracy of cancer
registrations in England and Scotland. Information on com-
pleteness of cancer registration is available from a small
number of specific studies (OPCS, 1993), which have shown
it to be about 90% in England for certain tumours (Swerd-
low et al., 1993). Completeness may vary between tumours,
but the histological diagnosis of carcinoid tumour is
relatively clear-cut, and likely, therefore, to be reliably
reported by pathology laboratories. We have also obtained
some direct evidence that registration of carcinoid tumours
has taken place with a reasonably high level ofcompleteness
and accuracy in parts of England. Our test ofcompkltness
was limited to a small number of patients and one geo-
graphical area (mainly the Oxford region) but was nonethe-
less reassuring.
The incidence of carcinoid tumours will have been under-
estimated if an appreciable number of tumours were not
registered because they were reported as benign. American
pathologists are said to report kss than 2% of all carcinoid
tumours explicitly as benign tumours (Godwin, 1975). The
clinical impression in the UK is that 'benign' carcinoid
tumours are rare and limited to those of the appendix.
Although the effect of excluding benign tumours is probably
small, the registation of carcinoid tumours would be
improved if, in future, all such tumours were registered.
Our estimates of the incidence of carcinoid tumours in
England and Scotland can be compared with those for other
population-based studies in the US and the UK. The largest
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study reported to date used data from cancer registries cover-
ing approximately 10% of the population of the US (God-
win, 1975). In that study of 970 cases, age-standardised
incidence rates ofcarcinoid tumour per 100,000 per year were
1.3 in males and 1.6 in females. Thus, Godwin found, as we
did, an excess of tumours in women, particularly tumours of
the appendix (F:M ratio 3.3:1), which he attributed to a
higher rate oflaparotomy and incidental diagnosis in women.
He also found a female excess for bronchial carcinoids (F:M
ratio 1.25:1) as at younger ages in our study. Godwin did
not report rates or sex ratios by age group but showed that
the average age of patients with appendiceal tumours (36
years) was less than for other sites (50 years for bronchial
tumours, 63 years for tumours of the small intestine), which
is also consistent with our results. Another American study
used cancer registry data but only looked at cancers of the
small intestine (Weiss & Yang, 1987). The unadjusted all-ages
incidence rate of these tumours was 0.29 per 100,000 per year
(n = 542). Incidence rates rose sharply after the age of 30
years.
We are aware of only two population-based studies of
carcinoid tumours from the UK. In Northern Ireland, from
1970 to 1985, 318 gastrointestinal carcinoid tumours were
ientified (Watson et al., 1989), giving an incidence rate of
1.3 per 100,000 per year. From 1979 to 1986, 70 cases were
recorded by Trent Cancer Registry (Woods et al., 1990). The
incidence rate was 0.7 per 100,000 per year.
Our results show a lower incidence rate for carcinoid
tumours in England than in Scotland. The rate for England
is also lower than Godwin's estimate of incidence in the US.
There was, however, some inconsistency in overall registra-
tion rates between English regional registries, which suggests
that incomplete registration by some registries (as, for exam-
ple, was the case in Wales) may partially explain the
relatively low rate in England.
It has been sug d by Godwin and others that the
female excess of abdominal carcinoids, which has also been
found in a number of case series (Thompson et al., 1985), is
largely explained by diagnostc bias owing to a higher
laparotomy rate in women. In support of this it is known,
from a study in the Oxford region, that incidental appen-
dicectomy (as opposed to appendicectomy for possible
appendicitis) is approximately five times as common m
women as in men throughout the reproductive age range
(Primatesta & Goldacre, 1994). Admissions for gall stones
are also much more common in women than men, the F:M
ratio in the age range 15-39 years was 5.7:1, again in the
Oxford region (M. Goldacre, personal communication). Fur-
thermore, carcinoids could be discovered during
gynaecological procedures including abdominal ultrasound
examination. The general female excess of carcinoid tumours
in the reproductive age range could, therefore, be due to
diagnois at laparotomy performed for other reasons.
On the other hand, there are reasons to question this
assumption. The F:M ratio ofappendicectomy rates (for any
indication) was only 1.43:1 at 15-19 years (Primatesta &
Goklacre, 1994), which was rather less than the F:M ratio of
incidence of abdominal carcinoids at the same age in Eng-
land, which was 2.14. A recently published case series
reported that 22 out of 41 appendiceal carcinoid tumours
presented with acute abdominal symptoms suggestive of
appendicitis (Roggo et al., 1993) and, of the 41 tumours, 33
(80%) were in women. As less than halfof the tumours were
found incidentally it seems unlikely that the female excess
was entirely explained by diagnostic bias. The most convinc-
ing evidence is that in our study and elsewhere bronchial
carcinoids are also more common inwomen than men under
50 years. An age-dependent diagnostic bias in favour of
females for bronchial tumours seems unlikely. Thus the data
suggest that the female excess at reproductive ages, and
perhaps also the peak ratio at 15-19, reflects a true sex
difference in incidence in addition to a diagnostic bias in
favour of females.
Several tumours arising in sites which are not sex specific
show marked age-specific sex differences in incidence, e.g.
Age group
Fugwe 4 Age- and sex-specific incidence rates of carcinoid
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cancers of the breast, thyroid and descending colon (dos
Santos Silva & Swerdlow, 1993), and seem likely to be
aetiologically influenced by sex hormones. We have shown
that a sex differential is also present for carcinoid tumours,
suggesting that endogenous hormones, particularly around
the time of puberty, might be important in their aetiology.
Oestrogen receptor protein has been identified in carcinoid
tumours (Keshgegian & Wheeler, 1980). This finding led to
trials of anti-oestrogen therapy in the carcinoid syndrome.
There was some early success (Myers et al., 1982), although a
later study of 16 patients with metastatic carcinoid tumours
showed no benefit from treatment with tamoxifen (Moertel et
al., 1984). The epidemiological information presented in this
paper suggests that the role of sex hormones as factors in the
growth and development of carcinoid tumours should be
investigated further.
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